$GH

Tariq Musa sold $15K of GH

Tariq Musa sold 116 shares of Guardant Health, Inc. (GH) at $130.19 on 2026-06-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Tariq Musa
Published Jun 16, 2026, 8:37 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 16, 2026, 8:42 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GH
Neutral
high confidence
Mentioned
$GH
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GHNeutralLow
01

Why it matters

This is a disclosed director open-market sale under a pre-arranged Rule 10b5-1 plan; absent other new company information, it is typically treated as low-signal for fundamentals.

02

Market read

Traders may note the insider sale for sentiment monitoring, but the filing alone is unlikely to drive a durable repricing.

03

What to watch

The article doesn’t state whether other insiders are buying/selling, nor the broader context of Musa’s total holdings beyond the post-transaction figure.

Relevance 2/10Novelty 6/10Timing: Filed 2026-06-16 (transaction dated 2026-06-16)

Background

The article is an SEC Form 4 insider transaction disclosure for Guardant Health, reported via EDGAR.

Company-level read

Ticker impact

$GHNeutralHigh confidence
Context

Guardant Health director Tariq Musa filed an SEC Form 4 selling 116 shares at $130.19 on 2026-06-16 under a 10b5-1 plan.

Expected impact

Likely minimal near-term impact; any reaction should be small and quickly mean-reverting.

Evidence & confidence

The filing is a small, pre-arranged 10b5-1 open-market sale by a director, with no accompanying operational/regulatory/financial catalyst in the text.

Market effects

No sector-level read-through; this is company-specific insider liquidity disclosure only.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can coincide with periods of valuation/positioning changes; traders may still watch for follow-on insider buys or larger transactions.

Key entities

  • Guardant Health, Inc.

    Company whose director insider transaction was disclosed on SEC Form 4.

  • Tariq Musa

    Director who sold 116 shares on 2026-06-16 under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GHMed

Guardant Health stock hits 52-week high at 176.68 USD

Guardant Health Inc. (GH) hit a 52-week high of $176.68, up 216.17% in a year. Q2 revenue grew 44% to $335M, beating expectations. Analysts raised price targets, with Stifel at $180 and TD Cowen at $210, both maintaining Buy ratings. Positive outlook driven by healthcare advancements and strong product performance.

$GHHighAI 9/10

Guardant Health (GH) Wins FDA Approval For First Liquid Biopsy In Advanced Breast Cancer

Guardant Health (GH) received FDA approval for Guardant360 CDx, a liquid biopsy test to monitor ctDNA in advanced breast cancer. The test guides treatment decisions before disease progression, targeting about 37,000 eligible patients in the US. This approval may influence oncologist testing habits, payer coverage, and Guardant's competitive position in cancer diagnostics.

$GHHighAI 9/10

Guardant Health Announces Landmark FDA Approval of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced Breast Cancer

Guardant Health (GH) received FDA approval for Guardant360 CDx as a companion diagnostic for AstraZeneca's ETCAMAH in advanced breast cancer. The approval, based on the SERENA-6 trial, showed a 56% reduction in disease progression risk when using ctDNA-guided treatment. The test is recommended for use every three months during therapy.

$GHHighAI 9/10

Final judgement favours TwinStrand in Guardant patent case

TwinStrand Biosciences and the University of Washington won a patent infringement case against Guardant Health, with the court awarding $245.2M in damages and royalties. The judgement upholds a jury verdict that Guardant willfully infringed two patents and must pay a 6% royalty on relevant sales until 2033. The court also affirmed the validity of the patents in question.